Lab Professionals
Take the right treatment path.
CA125 II is manufactured in a
proven high-quality process,
resulting in a consistent and dependable tumor marker assay.
CA125™ is the most widely used tumor marker worldwide for ovarian cancer and is indicated for use as an aid in the detection of residual ovarian carcinoma in patients who have undergone first-line therapy and would be considered for diagnostic follow-up procedures.
The CA125 monoclonal antibodies recognize epitopes in the protein core of the Muc 16 antigen. These monoclonal antibodies can be used for development of fast and sensitive homologous or heterologlous assays.
According to the ISOBM TD1 Workshop, CA125 contains 3 antigenic domains
- A-domain (Oc125)
- B-domain (M11)
- C-domain (Ov197)
| MAb | Isotype | Form | Prod. no. | Comments |
|---|---|---|---|---|
| Ov185 | IgG1 | Purified | 203-01 | B-domain (M11-like) |
| Ov197 | IgG1 | Purified | 212-01 | C-domain |
| OvK93 | IgG1 | Purified | 406-01 | A-domain (Oc125-like) |
| OvK95 | IgG1 | Purified | 407-01 | A-domain (Oc125-like) |
| OvK101 | IgG1 | Purified | 408-01 | B-domain (M11-like) |
| OC125 | IgG1 | purified | 201-850 | A-Domain |
| M11 | IgG1 | purified | 205-485 | B-Domain |
Improved Cancer Management
The CA125 radioimmunoassay is an in vitro diagnostic device for the quantitative measurement of OC 125 reactive determinants associated with a high-molecular-weight glycoprotein in the serum of women with primary epithelial invasive ovarian cancer, excluding those with cancer of low malignant potential.
It provides the following benefits
- Early detection of cancer recurrence
CA125 is indicated for use as an aid in the detection of residual ovarian carcinoma in patients who have undergone first-line therapy and would be considered for diagnostic second-look procedures. - Enhanced resolution at the low end
A second-generation assay, CA125II uses the M11 mouse monoclonal antibody as the new capture antibody. The addition of the M11 provides the benefit of increased sensitivity and detection at the low end of the curve, resulting in a clearer diagnostic picture and enhanced early disease detection. The M11 antibody is used in a dual monoclonal, heterogeneous format, enabling an easy, single-step procedure.
- Improved assay variability, clinically validated
CA125II has been proven in clinical use to provide a reduction in assay variability by approximately 50% over its predecessor marker.15 Utilized in a one-step protocol, CA125II results in minimal assay interference ad high inter-assay and intra-assay precision of less than 7% and 5% respectively. - Trusted and accepted by physicians worldwide
Supported by more than 2,000 peer-reviewed publications, CA125II is the most widely used tumor marker worldwide for ovarian cancer and is recommended by the National Institute of Health NIH to be a useful diagnostic tool for patient follow-up after surgery. CA125II is manufactured in a proven high-quality process, resulting in a consistent and dependable tumor marker assay.
View and download the Full Package Insert.
HE4: A Novel Serum Biomarker
A prospective study recently published in the journal, Gynecologic Oncology, found that women with elevated levels of a substance called HE4 in their blood might be more likely to have ovarian cancer.9 This is an encouraging find in the search for early detection of the disease, for which there is no adequate screening test. HE4 is not yet commercially available for sale in the US. Read more about this study.
